Abstract:Signal transducers and activators of transcription (STATs) are a family of transcription factors involved in the regulation of early embryonic development, immune response, cell proliferation, differentiation, and apoptosis. Particularly, STAT3 regulates lobuloalveolar apoptosis during involution in mammary gland development, and its activation is required for the growth of CD44+CD24- stem cell-like breast cancer cells and the development of multiple cancers including breast cancer. Increased STAT3 transcriptional activity was found to correlate with ER-negative phenotype in breast cancer cell lines and in primary human invasive ductal breast carcinomas. Thus, STAT3 represents a promising target for therapeutic and preventive intervention of breast cancer. Yet current strategies of inhibiting STAT3 activity did not sufficiently block STAT3 activation in cancer cells due to their limited potency, poor solubility or bioavailability. Despite several STAT3 inhibitors have been advanced into early clinical trials, there is an urgent need to develop a more successful strategy targeting STAT3 for cancer therapies, and preventive use in particular. We attempted to identify potent and orally active STAT3 inhibitors for such purposes and have designed, synthesized and screened a series of novel STAT3 inhibitors utilizing fragment-based drug design strategy. A number of small molecules with new scaffolds have been discovered with low-micromolar to nanomolar potency in inhibiting the proliferation of various human breast cancer and pancreatic cancer cells. The identified compound HJC0152 significantly suppresses basal and IL-6-stimulated STAT3 promoter activity and STAT3 phosphorylation, reduces total STAT3 protein expression, induces G2/M cell cycle arrest, and induces early apoptosis. HJC0152 has demonstrated a better potency in suppressing the growth of MDA-MB-231 breast xenograft tumors via intraperitoneal and oral administrative routes, with remarkably improved aqueous solubility (3,300 fold improvement) and less toxicity than the lead compounds. In conclusion, we have developed a new class of orally active STAT3 inhibitors with superior drug-like properties for further preclinical therapeutic and preventive evaluation. Citation Format: Zhengduo Yang, Haijun Chen, Lili Chu, Yusong Zhang, Chunyong Ding, Kristin Terry, Jia Zhou, Qiang Shen. Developing novel STAT3 inhibitors for the treatment and prevention of cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B63.

Novel Synthetic Bisindolylmaleimide Alkaloids Inhibit STAT3 Activation by Binding to the SH2 Domain and Suppress Breast Xenograft Tumor Growth.

Novel Synthetic Derivatives of the Natural Product Berbamine Inhibit Jak2/Stat3 Signaling and Induce Apoptosis of Human Melanoma Cells.

Novel Synthetic Berbamine Derivatives Inhibit Jak2/Stat3 Signaling And Induce Apoptosis Of Human Melanoma Cells

Physalin A Exerts Anti-Tumor Activity in Non-Small Cell Lung Cancer Cell Lines by Suppressing JAK/STAT3 Signaling.

Identification of New Shikonin Derivatives As Antitumor Agents Targeting Stat3 Sh2 Domain

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy

Small Molecule Induces Time‐Dependent Inhibition Of Stat3 Dimerization And Dna‐Binding Activity And Regresses Human Breast Tumor Xenografts

Design, synthesis, and biological evaluation of naphthoylamide derivatives as inhibitors of STAT3 phosphorylation

Identification of New Shikonin Derivatives As STAT3 Inhibitors.

Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide

Abstract 864: Novel synthetic berbamine derivatives inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion

Discovery, Synthesis, and Evaluation of Small-Molecule Signal Transducer and Activator of Transcription 3 Inhibitors

Design, Synthesis and Biological Evaluation of Benzyloxyphenyl-Methylaminophenol Derivatives As STAT3 Signaling Pathway Inhibitors.

Screening and Biological Evaluation of a Novel STAT3 Signaling Pathway Inhibitor Against Cancer.

Abstract B63: Developing Novel STAT3 Inhibitors for the Treatment and Prevention of Cancer

YL064 Directly Inhibits STAT3 Activity to Induce Apoptosis of Multiple Myeloma Cells

A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects

A Novel Stilbene Derivative (GMQ3) Suppressed Proliferation and Induced Apoptosis in Lung Cancer Via the P38-Mapk/sirt1 Pathway

Discovery, Optimization, and Evaluation of Novel N -(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment

Abstract 872: Novel Potent and Orally Active STAT3 Inhibitors for Cancer Therapies.